CD38 and acute myeloid leukemia: Highly expressed on CD34+CD38− AML LSCs; absent/low on normal HSCs but present on committed progenitors. Expression is associated with adverse prognosis. Reportedly upregulated after therapy in regenerative marrow. Ongoing clinical trials of CAR-T cells and antibody-drug conjugate targeting CD123